Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.78 |
| ▸ | PTGER2 | P43116 | 17/20 | 0.78 |
| ▸ | PTGER3 | P43115 | 17/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 10/20 | 0.78 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798324 | 1.00 | PTGER4 (0.78) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7807158 | 0.91 | PTGER3 (0.75) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7807162 | 0.91 | PTGER3 (0.75) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7957227 | 0.90 | PTGER4 (0.65) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL8323200 | 0.88 | PTGER4 (0.94) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL8323198 | 0.88 | PTGER4 (0.94) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7968873 | 0.83 | PTGER4 (0.84) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7968870 | 0.83 | PTGER4 (0.84) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL7955206 | 0.81 | PTGER4 (0.62) | PTGER4PTGER2PTGER3PTGER1PTGDR | |
| SCHEMBL8710177 | 0.79 | CCNB2 (0.66) | PTGER4PTGER2PTGER3PTGER1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000020371-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER4 11/4885PTGER2 2/4885PTGER3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.